Top Premarket Decliners
8:00AM ET 8/17/2022 MT NewswiresIterum Therapeutics (ITRM) shares slumped 18% after the company said it will implement a 1-for-15 reverse stock split. Artelo Biosciences (ARTL) shares...
Quotes Snapshot > ARTL
Artelo Biosciences Inc ARTL:NASDAQ
Last Price$5.12NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/18/22
Today's Change-0.23(4.30%)
Bid (Size)$5.00 (11)
Ask (Size)$5.14 (9)
Day Low / High$4.95 - 5.36
Volume278.8 K
Read more news Recent News
Top Midday Gainers
1:34PM ET 8/16/2022 MT NewswiresGreenBox POS (GBOX) late on Monday reported Q2 sales above market expectations. On Tuesday, GreenBox said it named J. Drew Byelick as its chief financial...
--HC Wainwright Lowers Price Target for Artelo Biosciences to $55 From $60, Maintains Buy Rating
10:18AM ET 8/12/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Artelo Biosciences Enrolls First Three Cohorts in Cancer-Related Anorexia, Weight-Loss Study
10:38AM ET 7/19/2022 MT NewswiresArtelo Biosciences (ARTL) said Tuesday it has completed enrollment of the first three cohorts in a study evaluating ART27.13 to treat cancer-related...
View all Commentary and Analysis
Artelo Biosciences (ARTL) Investor presentations - Slideshow
11:49AM ET 5/25/2022 Seeking AlphaArtelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy
9:18PM ET 3/08/2022 Seeking AlphaThe Carnage Under The Surface Of The Stock Market
1:51AM ET 1/25/2022 Seeking AlphaCompany Profile
Business DescriptionArtelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded by James Manley on May 2, 2011 and is headquartered in Solana Beach, CA. View company web site for more details
| Address | 505 Lomas Santa Fe Solana Beach, California 92075 |
| Phone | +1.858.925.7049 |
| Number of Employees | 2 |
| Recent SEC Filing | 08/12/2022 4 |
| President, CEO, CFO, Secretary & Treasurer | Gregory D. Gorgas |
| Vice President-Finance & Operations | Randy Schreckhise |
| Chief Medical Officer | Steven D. Reich |
| Chief Scientific Officer & Senior Vice President | Andy Yates |
Company Highlights
| Price Open | $5.23 |
| Previous Close | $5.35 |
| 52 Week Range | $3.61 - 19.80 |
| Market Capitalization | $216.6 M |
| Shares Outstanding | 42.3 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | N/A |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.28 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -46.49% |
Analyst Ratings as of 07/19/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |